[Comparison of the clinical outcomes of haploidentical and matched-sibling donor stem cell transplantation for T cell acute lymphoblastic leukemia in complete remission].

To compare the efficacy of haplotype hematopoietic stem cell transplantation (HIDT) and sibling matched hematopoietic stem cell transplantation (MSDT) in the treatment of complete remission (CR) acute T-lymphoblastic leukemia (T-ALL) . We retrospectively analyzed the clinical characteristics and outcomes of 98 patients who underwent HSCT in Hebei Yanda Ludaopei hospital with HID (=81) or ISD (=17) between May 2012 and May 2016. The incidence of grades 2-4 and 3-4 acute-versus-host disease 100 days after HSCT were 51.9% (95% Confidence interval [] 42.0%-64.0%) 29.4% (95% 14.1%-61.4%) (=0.072) and 9.8% (95% 5.1%-19.1%) 11.8% (95% 3.2%-43.3%) (=1.000) for HIDT and MSDT. The 100-day cumulative incidences of CMV and EBV viremia were 53.1% (95% 43.3%-65.2%) 29.4% (95% 14.1%-61.4%) (=0.115) and 35.8% (95% 26.8%-47.9%) 11.8% (95% 3.2%-43.3%) (=0.048) . The 5-year overall survival, leukemia-free survival, cumulative incidences of relapse, and no-relapse mortality were 60.5% (95% 5.4%-49.0%) 68.8% (95% 11.8%-40.0%) (=0.315) , 58.0% (95% 5.5%-46.5%) 68.8% (95% 11.8%-40.0%) (=0.258) , 16.1% (95% 9.8%-26.4%) 11.8% (95% 3.2%-43.3%) (=0.643) , 25.9% (95% 17.9%-37.5%) 19.4% (95% 6.9%-54.4%) (=0.386) for HIDT and MSDT, respectively. HID could be a valid alternative donor for patients with T-ALL in CR lacking an identical donor.